-

Aptatek BioSciences, Inc. Appoints Seasoned Healthcare Executive Lee McCracken to its Board of Directors

PRINCETON, N.J.--(BUSINESS WIRE)--Aptatek BioSciences, Inc., a developer of pioneering home monitoring tools for chronic disease patients, has appointed Drawbridge Health Chairperson Lee McCracken as a non-executive director. He joins Ali Tinazli, PhD, CEO of Lifespin Health, as part of the growing team of highly experienced industry professionals on Aptatek’s board of directors.

Lee has more than 30 years of pharmaceutical, biotech, diagnostics, device, and venture capital experience. He has held leadership and P&L roles in private and public companies, from startups to commercial stage.

Lee is Chairperson of Drawbridge Health, where he was previously recruited as CEO by GE Ventures and GE Healthcare. His extensive experience in corporate development, strategic partnering, fundraising, and M&A from Allergan to Prometheus Laboratories will be invaluable as Aptatek continues to develop home monitoring solutions that empower patients to take control of their health.

Mike Boyce-Jacino, PhD, CEO of Aptatek, said, “With a distinguished career in diagnostic and medical device development and a passion for improving the lives of patients, Lee brings a level of expertise and insight that will play a vital role in shaping our company's future.”

Jason Smith, PhD, Chairperson of Aptatek and Managing Director, Investment Partner at Longview Innovation, said, “Aptatek’s advanced technology has the potential to tap into a multi-billion-dollar market for at-home monitoring devices. Lee has deep knowledge of the space and practical experience in the commercialization of new technology, which we will call on to help us deliver the full potential of our technology.”

“I’m impressed with the technology being developed at Aptatek and their passion for providing individuals with chronic diseases the tools necessary to live healthier and more fulfilling lives,” said Lee. “I believe that collectively, we can revolutionize how chronic diseases are managed and improve patient outcomes worldwide."

For more information about Aptatek BioSciences and its innovative home monitoring solutions, please visit Aptatek BioSciences, Inc.

About Aptatek BioSciences, Inc.

Aptatek BioSciences, Inc. is a spinout of Columbia University at the forefront of developing home monitoring tools for chronic disease patients utilizing novel aptamer chemistry. With a mission to empower individuals with chronic diseases to manage their health more effectively, Aptatek BioSciences, Inc. combines cutting-edge aptamer technology, data-driven insights, and a patient-centric approach to revolutionize healthcare management. Aptatek hopes to revolutionize Phenylketonuria (PKU) monitoring and expand to other chronic disease states.

Contacts

Media Contact: Michael Boyce-Jacino at: info@aptatek.com

Aptatek BioSciences, Inc.


Release Versions

Contacts

Media Contact: Michael Boyce-Jacino at: info@aptatek.com

More News From Aptatek BioSciences, Inc.

Aptatek Biosciences Advances PheCheck™ Clinical Validation with Patient Enrollment Underway

PRINCETON, N.J.--(BUSINESS WIRE)--Aptatek Biosciences, Inc., a clinical-stage diagnostics company developing connected, aptamer-enabled technologies for decentralized metabolic monitoring, today announced that patient enrollment is underway in the PheCheck™ Validation Study (NCT07551921), advancing the company’s lead investigational program into formal clinical validation.The prospective study is evaluating PheCheck in people with phenylketonuria (PKU) and is designed to compare the performance...

Aptatek Biosciences Announces Initial Close of Financing to Advance PheCheck™ Clinical Program

PRINCETON, N.J.--(BUSINESS WIRE)--Aptatek closes financing to advance clinical evaluation of PheCheck™, its FDA Breakthrough-designated at-home monitoring system for PKU....

Aptatek BioSciences, Inc. Announces Bridge Financing to Support Advancement of the PheCheck™ Aptamer-based In-home Monitoring Platform

PRINCETON, N.J.--(BUSINESS WIRE)--Aptatek BioSciences, Inc., a pioneer in developing innovative in-home monitoring solutions for patients managing chronic diseases, today announced it has received bridge financing from Canterbury Scientific, Ltd, a current strategic investor. This latest funding tranche follows the successful advancement of Aptatek’s PheCheck™ platform, an FDA breakthrough diagnostic device designed for at-home monitoring of phenylalanine levels in patients with phenylketonuria...
Back to Newsroom